The University of Chicago Header Logo

Connection

Everett Vokes to Indoles

Back to Details
This is a "connection" page, showing publications Everett Vokes has written about Indoles.
Everett Vokes
Connection Strength
1.496
Indoles
  1. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol. 2017 05; 12(5):843-849.
    View in: PubMed
    Score: 0.453
  2. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20; 33(15):1660-5.
    View in: PubMed
    Score: 0.397
  3. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
    View in: PubMed
    Score: 0.188
  4. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). J Thorac Oncol. 2016 Mar; 11(3):361-9.
    View in: PubMed
    Score: 0.105
  5. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24.
    View in: PubMed
    Score: 0.073
  6. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
    View in: PubMed
    Score: 0.067
  7. Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
    View in: PubMed
    Score: 0.064
  8. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
    View in: PubMed
    Score: 0.023
  9. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):214-21.
    View in: PubMed
    Score: 0.023
  10. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84.
    View in: PubMed
    Score: 0.023
  11. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
    View in: PubMed
    Score: 0.019
  12. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
    View in: PubMed
    Score: 0.017
  13. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.016
  14. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
    View in: PubMed
    Score: 0.016
  15. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.